LYEL$15.4343.27%4.66
After Hours: 15.74+0.31 +2.01%
Lyell Immunopharma Inc (LYEL)
Date: 2026-11-04 16:00O: 12.09H: 16.73L: 12.09C: 15.43Vol: 1.101M
Lyell Immunopharma Inc stock is traded at $15.43, with a volume of 1,100,515. It is up +43.27% in the last 24 hours and up +66.63% over the past month. Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
Previous Close:
$10.77
Open:
$12.09
24h Volume:
1,100,515
Relative Volume:
5.22
Market Cap:
$378.11M
Revenue:
$31,000
Net Income/Loss:
-$246.41M
P/E Ratio:
-
EPS:
-$12.74
Net Cash Flow:
-$134.42M
1W Performance:
+41.17%
1M Performance:
+66.63%
6M Performance:
-25.53%
1Y Performance:
-3.26%
1-Day Range:
$12.09$16.73
1-Week Range:
$10.56$16.73
52-Week Range:
$7.20$45.00
Lyell Immunopharma Inc Stock (LYEL) Company Profile
Name
Lyell Immunopharma IncSector
HealthcareIndustry
BiotechnologyPhone
650 695-0677Address
201 HASKINS WAY, SOUTH SAN FRANCISCO, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS
Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades
Lyell Immunopharma Inc Stock (LYEL) Financials Data
Lyell Immunopharma Inc Stock (LYEL) Insider Trading
- Aguirre Jarrad MattieuOct 12 '26Chief Medical Officer
- Transaction
- Sale
- Cost
- $8.63
- #Shares
- 422
- Value ($)
- 3,642
- #Shares Total
- 19,857
- Shook DavidSep 10 '26Chief Medical Officer
- Transaction
- Sale
- Cost
- $12.70
- #Shares
- 500
- Value ($)
- 6,350
- #Shares Total
- 20,423
- Hill Stephen J.Aug 21 '26Chief Operating Officer
- Transaction
- Sale
- Cost
- $15.54
- #Shares
- 989
- Value ($)
- 15,369
- #Shares Total
- 16,816
- Seely LynnAug 21 '26President and CEO
- Transaction
- Sale
- Cost
- $15.54
- #Shares
- 9,589
- Value ($)
- 149,013
- #Shares Total
- 63,899
- Lee Gary K.Aug 21 '26Chief Scientific Officer
- Transaction
- Sale
- Cost
- $15.54
- #Shares
- 1,457
- Value ($)
- 22,642
- #Shares Total
- 16,220
- Hill Stephen J.Aug 10 '26Chief Operating Officer
- Transaction
- Sale
- Cost
- $14.34
- #Shares
- 89
- Value ($)
- 1,276
- #Shares Total
- 17,805
- Seely LynnAug 10 '26President and CEO
- Transaction
- Sale
- Cost
- $14.34
- #Shares
- 390
- Value ($)
- 5,593
- #Shares Total
- 73,488
- Lee Gary K.Aug 10 '26Chief Scientific Officer
- Transaction
- Sale
- Cost
- $14.34
- #Shares
- 131
- Value ($)
- 1,879
- #Shares Total
- 17,677
- Bulis Veronica SanchezAug 10 '26VP, Corporate Controller
- Transaction
- Sale
- Cost
- $14.34
- #Shares
- 621
- Value ($)
- 8,905
- #Shares Total
- 14,799
- Innovative Cellular TherapeutiJul 17 '2610% Owner
- Transaction
- Sale
- Cost
- $13.70
- #Shares
- 10
- Value ($)
- 137
- #Shares Total
- 2,857,480
